| |
 |
| |
 |
Siena Biotech
drug discovery process is focused on
developing therapies for unmet medical
needs in a range of CNS and Proliferative
diseases including rare diseases. In
particular we are concentrating on neurodegeneration
and brain tumour applications, via small
molecule entry points against key disease
targets that will provide modulators
of significant therapeutic value.
Innovation and excellence in science
are cornerstones of our drug discovery
process. We are committed to
taking full advantage of the opportunities
presented by combining in-depth experience
of drug discovery in the pharmaceutical
industry, the flexibility and entrepreneurial
spirit of a biotech, and sound financial
support.
To support the drug discovery process
from target identification and validation
through to PoC studies (Phase IIa),
the company is applying state-of-the-art
skills in technologies from biomedical
and biotechnology fields ranging from
differential proteomics and pathway
analysis to drug profiling and knowledge
based drug design that will significantly
enhance our ability to deliver innovative
products to CNS markets.
Strategic alliances and collaborations
with Pharma/Biotech Companies allow
us to achieve these goals in a timely
fashion.
|
|
|
|
|
|
